|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008838,
umls-concept:C0008972,
umls-concept:C0030705,
umls-concept:C0034897,
umls-concept:C0040808,
umls-concept:C0205177,
umls-concept:C0205179,
umls-concept:C0246415,
umls-concept:C0282460,
umls-concept:C0334246,
umls-concept:C0460004,
umls-concept:C1257890,
umls-concept:C1274040,
umls-concept:C1516985,
umls-concept:C1517927
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1999-4-29
|
|
pubmed:abstractText |
Docetaxel and cisplatin are among the most active antitumor agents in head and neck cancer, and phase I studies found the combination of the two drugs to be feasible. The EORTC ECSG performed a multicenter phase II study in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck to evaluate the antitumor efficacy and toxicity of this combination.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
119-22
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10076732-Adult,
pubmed-meshheading:10076732-Aged,
pubmed-meshheading:10076732-Antineoplastic Agents,
pubmed-meshheading:10076732-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:10076732-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10076732-Carcinoma, Squamous Cell,
pubmed-meshheading:10076732-Cisplatin,
pubmed-meshheading:10076732-Disease-Free Survival,
pubmed-meshheading:10076732-Female,
pubmed-meshheading:10076732-Head and Neck Neoplasms,
pubmed-meshheading:10076732-Humans,
pubmed-meshheading:10076732-Male,
pubmed-meshheading:10076732-Middle Aged,
pubmed-meshheading:10076732-Neoplasm Recurrence, Local,
pubmed-meshheading:10076732-Paclitaxel,
pubmed-meshheading:10076732-Prognosis,
pubmed-meshheading:10076732-Survival Rate,
pubmed-meshheading:10076732-Taxoids,
pubmed-meshheading:10076732-Treatment Outcome
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
|
|
pubmed:affiliation |
Department of Hematology-Oncology, Hannover University Medical School, Germany. patrick_schoffski@compuserve.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
